Risk factors for recurrent primary sclerosing cholangitis after liver transplantation
Reena Ravikumar, Andrew K. Burroughs(University College London), Parthi Srinivasan(King's College - North Carolina), Mansoor Madanur(King's College - North Carolina), Michael Allison(Cambridge University Hospitals NHS Foundation Trust), Keith Roberts(University of Alabama at Birmingham Hospital), Andrea del Monaco(The Royal Free Hospital), Bridget Gunson(NIHR Birmingham Liver Biomedical Research Unit), Giuseppe Fusai(The Royal Free Hospital), Nicola Owen(Cambridge University Hospitals NHS Foundation Trust), Sophie José(NHS England), Stephen J. Wigmore(Edinburgh Royal Infirmary), Derek Manas, Anuja Athale(King's College - North Carolina), Felicity Creamer(Edinburgh Royal Infirmary), Vikram Iyer(NIHR Birmingham Liver Biomedical Research Unit), Bimbi Fernando(The Royal Free Hospital), Emmanuel Tsochatzis(University College London), Gourab Sen(Freeman Hospital), Darius F. Mirza(Apollo Hospitals)
Cited by 172
Related Papers
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
|Journal of Hepatology|2001|4.1k
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis
|The Lancet Oncology|2008|2k
Human primary liver cancer–derived organoid cultures for disease modeling and drug screening
|Nature Medicine|2017|1.5k
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
|Nature|2021|1.3k